OUR SCIENCE
BYQMed's technology is built on four decades of nucleolar protein research led by Professor Benjamin Yat-Ming Yung. Our proprietary Quantitative Gene Co-expression Test (QGCT®) decodes the NPM1/B23-centered pathway networks driving drug resistance and recurrence, translating deep molecular biology into clinically actionable, personalized cancer care.
THE SCIENCE BEHIND QGCT®
Nucleophosmin (NPM1/B23) is a multifunctional nucleolar protein central to ribosome biogenesis, DNA repair, and centrosome duplication. Professor Yung's laboratory has spent over 40 years characterizing how dysregulation of NPM1/B23 destabilizes genomic integrity and drives oncogenic transformation, publishing foundational work in journals including Hepatology, EMBO Reports, and Cellular Signalling.
This molecular foundation evolved into a computational framework: genome-wide gene co-expression network analysis. By mapping how all 20,000+ protein-coding genes interact around NPM1/B23-centered hubs, we can identify which regulatory pathways become dysregulated in a given tumor — and which of those pathways are driving resistance, recurrence, or treatment failure.
QGCT® PIPELINE
QGCT® (Quantitative Gene Co-expression Test) is a tissue RNA-based, Software-as-a-Medical-Device (SaMD) platform that combines RNA sequencing, bioinformatics, and machine learning to map genome-wide co-expression networks. Rather than looking at single biomarkers, QGCT® analyzes the complete interaction landscape among all 20,000+ genes to identify which regulatory pathways are dysregulated in a patient's tumor.
Active service pipeline: Ovarian QGCT® (HGSOC chemoresistance), Breast QGCT® (HER2+ recurrence), Lung NSCLC QGCT®, Lung SCLC QGCT®, Colorectal QGCT® (post-surgical recurrence risk), and Hepatocarcinoma QGCT® (including HBV-associated HCC). Additional indications are under ongoing research and development.